Leukine Articles
Bayer publishes Leukine trial results
14 July 2008
Bayer reports strong results in Leukine trial
16 June 2008
Bayer debuts reformulated Leukine in USA
26 May 2008
Bayer USA withdraws Leukine 500mcg vials
4 February 2008
Favrille signs FavID accord with Berlex
19 February 2007
Anti-TNF drug sales to hit $1.3B by 2015
22 December 2006
Sargramostim falls short in Crohn's trials
7 August 2006
Berlex to invest $60M into biopharm center
26 July 2004
Berlex acquires 16-acre site for manufacturing
5 July 2004
Stock Commentary - Europe
20 October 2003
Schering AG US sales up 22% in Q2
5 August 2002
US FTC OKs Amgen/Immunex merger
22 July 2002
Stock Commentary - New York
13 May 2002
Strong 2000 results for Immunex
26 January 2001
A Real Challenge To HIV With New Therapies?
12 February 1998
Stock Commentary New York
12 February 1998
US 3rd Quarter Results Show Strong Growth
22 October 1997
CEL-SCI: AIDS Vaccine Data
9 October 1997
New Advances In The Treatment Of Sepsis?
9 October 1997
Leukine On Track For Melanoma Indication
26 March 1997
US Biopharma Firms See Research Bear Fruit In '96
17 February 1997
US Approves Immunex' Liquid Leukine
18 November 1996
What Future For Biotechnology At AHP?
15 April 1996
FDA Approval For Immunex' Etoposide
25 March 1996
Important Developments For US Biotechnology Cos
19 February 1996
FDA Year-End Approvals Round-Up
8 January 1996
Immunex gets Leukine approval
4 December 1995
Neupogen And Leukine Backed For Peripheral Blood Transplantation
20 November 1995
Phase III Results For Pixykine In Bone Marrow Transplant
6 November 1995
US Drug Firms Perform Well In Third Quarter
6 November 1995
New York stock comment
6 November 1995
Immunex' Leukine Gains FDA Approval For AML
25 September 1995
Leukine Recommendation
17 April 1995
New York Stock Comment
3 April 1995
New Indication For Immunex' Leukine
27 February 1995
NEW YORK STOCK COMMENT
12 December 1994
Solid 3rd Qtr Growth For Large Pharma Cos
31 October 1994
AHP Bid For Cyanamid Will Broaden Product Range
15 August 1994
Hoechst Products to Be Boycotted In The USA
18 July 1994
Schering-Plough's Cytokine Research
18 July 1994
NEUPOGEN APPROVED FOR BMT IN USA
27 June 1994
IMMUNEX AIMS FOR THREE DRUGS IN CLINIC IN 1994
21 February 1994
WORLD HEMATOLOGY MARKET FORECASTS
24 January 1994
BETAFECTIN STARTS PHASE III TRIALS
17 January 1994
PMA WARNING ON FUTURE OF BIOTECHNOLOGY
27 September 1993
NICHE MARKETING IN THE BIOTECH INDUSTRY
26 July 1993
BIOTECH PRODUCTS INUS DEVELOPMENT
26 July 1993
US BIOTECH FIRMS POST GOOD 1st QTRs
17 May 1993
US BIOTECHNOLOGY COS REPORT 1992 RESULTS
15 March 1993
IMCLONE HEADING FOR COMMERCIALIZATION
1 March 1993
USE OF GROWTH FACTORS IN AIDS MANAGEMENT
7 September 1992
IMMUNEX TO GAIN CONTROL OF US GM-CSF MARKET
3 August 1992
GOOD GROWTH FOR US COMPANIESCONTINUES FOR US COs
3 August 1992
ANALYSTS OPTIMISTIC ON IMMUNEX
4 May 1992
GOOD 1st QTRs for ALZA, IMMUNEX AND MYLAN
4 May 1992
NEW CHEMICAL ENTITIES UPDATE FOR 1991
10 February 1992
STOCK MARKET COMMENTARY: NEW YORK
10 February 1992
Showing 1-66 of 66 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
